December 5, 2025Hematology

The role of MRD monitoring and options for CLL management in relapsed/refractory disease

View Full Paper

Ask AI

Bookmark

Authors

TSTanya SiddiqiCity Of Hope National Medical Center

Discussion

Member takes

Implication

Investigation reveals minimal residual disease monitoring enhances outcomes in chronic lymphocytic leukemia, suggesting improvements in relapsed treatment options.

Key Points

Monitoring minimal residual disease may lead to better treatment decisions in chronic lymphocytic leukemia.
Current MRD testing shows promise in hematological malignancies, but remains investigational for CLL.
Targeted therapies alongside MRD monitoring could yield deeper remissions, particularly in relapsed cases.
Prospective interventional trials are essential to define optimal MRD testing applications in CLL.

Cite This Study

Tanya Siddiqi (2025) studied this question.

synapsesocial.com/papers/6940224e2d562116f28fc11a https://doi.org/10.1182/hematology.2025000685

View Full Paper

Ask AI

Bookmark

Implication

Investigation reveals minimal residual disease monitoring enhances outcomes in chronic lymphocytic leukemia, suggesting improvements in relapsed treatment options.

The role of MRD monitoring and options for CLL management in relapsed/refractory disease

Discussion

Member takes

Implication

Key Points

Cite This Study

The role of MRD monitoring and options for CLL management in relapsed/refractory disease

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider